Estimation of safe and effective dose of vancomycin in mrsa-infected patients using serum cystatin c concentrations

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 3, 2013, Pages 161-169

  Chen, Yu Chun ^a   Feng, Jia Fu ^a   Li, Bing ^b   Zhang, Ling ^a   Yang, Yu Wei ^a  

^a Mianyang Central Hospital   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Clearance; Cystatin C; Drug monitoring; Glomerular filtration rate; Vancomycin

Indexed keywords

CREATININE; CYSTATIN C; VANCOMYCIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTINUOUS INFUSION; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; STEADY STATE; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84874694725     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201776     Document Type: Article

References (43)

1. Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007; 44: 1536-1542. doi:10.1086/518451 PubMed
2. Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2012; 51: 1-13. doi:10.2165/11596390-000000000-00000 PubMed
3. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf. 2010; 9: 9-14. doi:10.1517/14740330903413514 PubMed
4. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycintreated patients. Antimicrob Agents Chemother. 2011; 55: 3278-3283. doi:10.1128/AAC.00173-11 PubMed
5. Cadle RM, Mansouri MD, Darouiche RO. Vancomycin-induced elevation of liver enzyme levels. Ann Pharmacother. 2006; 40: 1186-1189. doi:10.1345/aph. 1G668 PubMed
6. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother. 2009; 53: 483-486. doi:10.1128/AAC.01088-08 PubMed
7. Rello J, Sole-Violan J, Sa-Borges M, Garnacho-Montero J, Muñoz E, Sirgo G, Olona M, Diaz E. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med. 2005; 33: 1983-1987. doi:10.1097/01.CCM.0000178180.61305.1D PubMed
8. Okamoto G, Sakamoto T, Kimura M, Ukishima Y, Sonoda A, Mori N, Kato Y, Maeda T, Kagawa Y. Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin Biochem. 2007; 40: 485-490. doi:10.1016/j.clinbiochem.2007.01.008 PubMed
9. Norazah A, Salbiah N, Nurizzat M, Santhana R. Vancomycin treatment failure in a vancomycin susceptible methicillin-resistant Staphylococcus aureus (MRSA) infected patient. Med J Malaysia. 2009; 64: 166-167. PubMed
10. Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2011; 66: 1594-1599. doi:10.1093/jac/dkr169 PubMed
11. Lubin AS, Snydman DR, Ruthazer R, Bide P, Golan Y. Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections. Clin Infect Dis. 2011; 52: 997-1002. doi:10.1093/cid/cir118 PubMed
12. Tanaka A, Aiba T, Otsuka T, Suemaru K, Nishimiya T, Inoue T, Murase M, Kurosaki Y, Araki H. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother. 2010; 54: 778-782. doi:10.1128/AAC.00661-09PubMed
13. Liu J. Evaluation of serum cystatin C for diagnosis of acute rejection after renal transplantation. Transplant Proc. 2012; 44: 1250-1253. 10.1016/j. transproceed.2012.01
14. Cai X, Long Z, Lin L, Feng Y, Zhou N, Mai Q. Serum cystatin C is an early biomarker for assessment of renal function in burn patients. Clin Chem Lab Med. 2012; 50: 667-671. doi:10.1515/cclm-2011-0838 PubMed
15. Krishnamurthy N, Arumugasamy K, Anand U, Anand CV, Aruna V, Venu G. Serum cystatin C levels in renal transplant recipients. Indian J Clin Biochem. 2011; 26: 120-124. doi:10.1007/s12291-010-0084-0 PubMed
16. Kumaresan R, Giri P. A comparison of serum cystatin C and creatinine with glomerular filtration rate in Indian patients with chronic kidney disease. Oman Med J. 2011; 26: 421-425. doi:10.5001/omj.2011.107 PubMed
17. Yap M, Lamarche J, Peguero A, Courville C. Serum cystatin C versus serum creatinine in the estimation of glomerular filtration rate in rhabdomyolysis. J Ren Care. 2011; 37: 155-157. doi:10.1111/j.1755-6686.2011.00228.x PubMed
18. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002; 40: 221-226. doi:10.1053/ajkd.2002.34487 PubMed
19. Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilatorassociated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med. 2006; 34: 700-706. doi:10.1097/01. CCM.0000201885.57697.21 PubMed
20. Tanaka A, Suemaru K, Araki H. A new approach for evaluating renal function and its practical application. J Pharmacol Sci. 2007; 105: 1-5. doi:10.1254/jphs.CP0070058 PubMed
21. Suzuki A, Imanishi Y, Nakano S, Niwa T, Ohmori T, Shirai K, Yoshida S, Furuta N, Takemura M, Ito H, Ieiri I, Seishima M, Ogura S, Itoh Y. Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients. J Pharm Pharmacol. 2010; 62: 901-907. PubMed
22. Kees MG, Hilpert JW, Gnewuch C, Kees F, Voegeler S. Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C. Int J Antimicrob Agents. 2010; 36: 545-548. doi:10.1016/j.ijantimicag.2010. 07.015 PubMed
23. Tanaka A, Suemaru K, Otsuka T, Ido K, Nishimiya T, Sakai I, Hasegawa H, Yasukawa M, Inoue T, Murase M, Araki H. Hoek's formula, a cystatin C-based prediction formula for determining the glomerular filtration rate, is the most effective method for original adjusting the dosage of vancomycin. Int J Clin Pharmacol Ther. 2007; 45: 592-597. PubMed
24. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17: 2937-2944. doi:10.1681/ASN.2006040368 PubMed
25. World Health Organization. Use of anticoagulants in diagnostic laboratory investigations. Geneva, 15 January 2002. WHO/DIL/LAB/99.1 Rev. 2 (http://whqlibdoc.who.int/hq/2002/WHO-DIL-LAB-99.1-Rev.2.pdf).
26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41. doi:10.1159/000180580 PubMed
27. Flodin M, Jonsson AS, Hansson LO, Danielsson LA, Larsson A. Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in ml/min/1.73 m(2) from the cystatin C values in mg/L. Scand J Clin Lab Invest. 2007; 67: 560-567. doi:10.1080/00365510601187773 PubMed
28. Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, Viale P. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2009; 53: 1863-1867. doi:10.1128/AAC.01149-08 PubMed
29. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008; 62: 168-171. doi:10.1093/jac/dkn080 PubMed
30. Soares AA, Eyff TF, Campani RB, Ritter L, Camargo JL, Silveiro SP. Glomerular filtration rate measurement and prediction equations. Clin Chem Lab Med. 2009; 47: 1023-1032. doi:10.1515/CCLM.2009.263 PubMed
31. Zahran A, El-Husseini A, Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol. 2007; 27: 197-205. doi:10.1159/000100907 PubMed
32. Nielsen EI, Sandström M, Honoré PH, Ewald U, Friberg LE. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet. 2009; 48: 253-263. doi:10.2165/00003088-200948040-00003 PubMed
33. Moore CL, Lu M, Cheema F, Osaki-Kiyan P, Perri MB, Donabedian S, Haque NZ, Zervos MJ. Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool. Antimicrob Agents Chemother. 2011; 55: 4581-4588. doi:10.1128/AAC.00115-11 PubMed
34. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012; 54: 51-58. doi:10.1093/cid/cir764 PubMed
35. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2011; 66: 2386-2392. doi:10.1093/jac/dkr301 PubMed
36. Clemens EC, Chan JD, Lynch JB, Dellit TH. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2011; 71: 408-414. doi:10.1016/j. diagmicrobio.2011.08.002 PubMed
37. Frymoyer A, Guglielmo BJ, Wilson SD, Scarpace SB, Benet LZ, Hersh AL. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy. 2011; 31: 871-876. doi:10.1592/phco.31.9.871 PubMed
38. Huang WC, Lee CH, Liu JW. Clinical characteristics and risk factors for mortality in patients with meningitis caused by Staphylococcus aureus and vancomycin minimal inhibitory concentrations against these isolates. J Microbiol Immunol Infect. 2010; 43: 470-477. doi:10.1016/S1684-1182(10)60073-4 PubMed
39. Salgado JV, Neves FA, Bastos MG, França AK, Brito DJ, Santos EM, Salgado Filho N. Monitoring renal function: measured and estimated glomerular filtration rates-A review. Braz J Med Biol Res. 2010; 43: 528-536. doi:10.1590/S0100-879X2010007500040 PubMed
40. Stevens LA, Padala S, Levey AS. Advances in glomerular filtration rate-estimating equations. Curr Opin Nephrol Hypertens. 2010; 19: 298-307. doi:10.1097/MNH.0b013e32833893e2 PubMed
41. Chew JS, Saleem M, Florkowski CM, George PM. Cystatin C-A paradigm of evidence based laboratory medicine. Clin Biochem Rev. 2008; 29: 47-62. PubMed
42. Viollet L, Gailey S, Thornton DJ, Friedman NR, Flanigan KM, Mahan JD, Mendell Jr. Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve. 2009; 40: 438-442. doi:10.1002/mus.21420 PubMed
43. Gerbes AL, Gülberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut. 2002; 50: 106-110. doi:10.1136/gut.50.1.106 PubMed